All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
In the December 2017 issue of the American Journal of Hematology, Courtney D. DiNardo from the University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, and colleagues published results of their study, which aimed to determine the efficacy and safety of venetoclax (VEN [an oral, selective BCL2 inhibitor]) combination strategies in the salvage setting in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and/or associated myeloid malignancies including Myelodysplastic Syndromes (MDS) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
In total, 43 patients (median age = 68, range, 25–83 years) with R/R AML (n = 39), MDS (n = 2) or BPDCN (n = 2), who were treated with VEN salvage combination regimens between 10 June 2016 and 6 July 2017 at the MDACC were analyzed in this study. Patients received ≥ 14 Days of VEN with either Hypomethylating Agents (HMAs), azacitidine (n = 8) or decitabine (n = 23) or Low-Dose Cytarabine (LDAC [n = 8]) or other (n = 4).
In summary, this is the first study to report on the “effectiveness of VEN combination strategies for R/R myeloid population”. The authors stated that their findings demonstrate that low-dose chemotherapy either with HMAs or LDAC, in combination with VEN is a “viable salvage treatment” and provides an alternative therapy option for patients with R/R AML, MDS, and BPDCN. Moreover, responses were observed in patients with diploid/intermediate cytogenetics, RUNX1, and/or IDH1/2 mutations.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?